Showing results (41-50 of 375) with videos related to

Sort By:
Pageof 38
World Journal of Nuclear Medicine|February 17, 2025
Metastatic Malignant Paraganglioma of Rare Sites Failed on Conventional Treatments Demonstrating Beneficial Response to <sup>177</sup> Lu-DOTATATE PRRTYeshwanth Edamadaka, Munita Bal, Swapnil Rane, et al.
Endocrine|March 25, 2025
Evaluating the prognostic significance of the pre-treatment neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios in <sup>177</sup>Lu-DOTATATE PRRT treated patients with advanced metastatic neuroendocrine tumorsMahesh K Padwal, Amir K Nazar, Rahul V Parghane, et al.
Clinical Nuclear Medicine|July 14, 2020
Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE TreatmentRahul V Parghane, Arpit Mitra, Trupti Upadhye, et al.
The Prostate|September 1, 2021
Combined <sup>177</sup> Lu-PSMA-617 PRLT and abiraterone acetate versus <sup>177</sup> Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durabilitySonam Suman, Rahul V Parghane, Amit Joshi, et al.
World Journal of Nuclear Medicine|April 14, 2021
Initial clinical evaluation of indigenous <sup>90</sup>Y-DOTATATE in sequential duo-PRRT approach (<sup>177</sup>Lu-DOTATATE and <sup>90</sup>Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, <sup>90</sup>Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effectsRahul V Parghane, Arpit Mitra, Trupti Upadhye Bannore, et al.
Head & Neck|November 23, 2019
Clinical utility of <sup>177</sup> Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicityRahul V Parghane, Chinna Naik, Sanjay Talole, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 25, 2026
Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/MLSandip Basu, Shyam Kumar Ravada, Rahul V Parghane, et al.
The British Journal of Radiology|October 11, 2019
Therapeutic efficacy, prognostic variables and clinical outcome of <sup>177</sup>Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohortSonam Suman, Rahul V Parghane, Amit Joshi, et al.
Journal of Neuroendocrinology|November 14, 2024
Developing a peripheral blood RNA-seq based NETseq ensemble classifier: A potential novel tool for non-invasive detection and treatment response assessment in neuroendocrine tumor patients receiving <sup>177</sup>Lu-DOTATATE PRRTMahesh K Padwal, Rahul V Parghane, Avik Chakraborty, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 3, 2020
Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive diseaseRahul V Parghane, Vikas Ostwal, Anant Ramaswamy, et al.
Pageof 38